On August 18, 2026, Genprex, Inc. announced a development and manufacturing agreement with a leading U.S.-based Contract Development and Manufacturing Organization to initiate the manufacturing scale-up of its diabetes gene therapy program. This partnership transitions the therapeutic candidate from research-grade production to clinical and commercial-ready output using cGMP-compliant facilities. The CDMO will supply drug product for IND-enabling preclinical studies and future trials, focusing on process optimization, scale-up via capacity bioreactors, analytical qualification, and GMP compliance. Genprex is a biotechnology company developing gene therapies for Type 1 and Type 2 diabetes.
